PODD Drug Delivery Conference Announces 2025 Keynotes
NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA.
"In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference.
The PODD 2025 keynotes include:
MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry.
Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work.
Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally.
Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety.
The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies.
To learn more about the event, visit PODDConference.com
About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations.
About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking.
Learn more about the Conference Forum at theconferenceforum.org.
For media inquiries, contact:Bre Bugbee-Barrettbre@tcfllc.org
View original content:https://www.prnewswire.com/news-releases/podd-drug-delivery-conference-announces-2025-keynotes-302484499.html
SOURCE Partnership Opportunities in Drug Delivery (PODD)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
a minute ago
- CNN
Target's CEO is stepping down as sales continue to plunge
Target CEO Brian Cornell is stepping down after 11 years at the retailer, as the company faces slumping sales and backlash to its retreat on DEI. Cornell will be replaced on February 1, 2026, by Michael Fiddelke, Target's chief operating officer. This is a breaking news story and will be updated.
Forbes
a minute ago
- Forbes
SoundHound AI: SOUN Stock To $2?
SoundHound AI (NASDAQ: SOUN), a voice AI platform that helps businesses deliver conversational AI experiences, has certainly attracted investor interest with its AI-led growth narrative. However, the stock's history of sharp swings and recent market setup point to meaningful downside risk. The recent 10% drop on August 19, as investors took profits across growth names, underscores SOUN's sensitivity to shifts in market sentiment. Now, if you prefer upside potential with less volatility than owning a single stock, consider the High Quality Portfolio, which has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P midcap index—and has delivered returns exceeding 91% since inception. Also see – GE Stock To $500? Extreme Historical Volatility SoundHound's history shows a pattern of severe drawdowns during periods of market stress. Prior episodes offer a sober reference point for investors: This volatility reflects SOUN's profile as a high-beta growth name. With a beta near 3, SoundHound tends to move more than three times the broader market in both directions. See – Buy or Fear SOUN Stock? Fundamental Concerns Mounting Several fundamental pressures could deepen the downside: Market Structure Risks Structural dynamics could accelerate downside moves: Recession Scenario Impact A broader downturn could pressure key customer segments: The Path to $2 A 90% slide from recent peaks of about $20 implies a price near $2 per share. While extreme, similar moves have occurred. A deep recession could spark widespread de-risking, hitting high-beta growth stocks hardest. Earnings disappointments—missing revenue targets or pushing out profitability—can quickly erode confidence and prompt institutional selling. Heightened competition from large tech companies could also threaten SoundHound's positioning and growth outlook. If sentiment shifts away from AI and growth toward defensive sectors, SOUN's high-volatility profile leaves it exposed. Finally, in a liquidity crunch, institutions often sell their most volatile holdings first—stocks like SOUN can bear the brunt. The Verdict SoundHound AI operates in an attractive market, but its shares carry exceptional downside risk. The mix of extreme volatility, unproven profitability, and sentiment sensitivity creates conditions for severe drawdowns. History shows SOUN can fall 90% during market stress—a pattern that could recur if economic or sector headwinds build. This analysis zeroes in on downside risk and complements our separate assessment of upside drivers. For investors, position sizing and risk controls are essential with such high-volatility profiles. We apply a risk framework when constructing the Trefis High Quality (HQ) Portfolio, which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks have delivered better returns with less risk versus the benchmark—less of a roller-coaster ride—as shown in HQ Portfolio performance metrics.
Wall Street Journal
2 minutes ago
- Wall Street Journal
Estee Lauder Loss Widens as Sales Fall
Estee Lauder EL -0.96%decrease; red down pointing triangle posted a wider loss in the fiscal fourth quarter as sales continued to struggle, sending shares lower in premarket trading Wednesday. The beauty company behind MAC, Smashbox and Jo Malone posted a loss of $546 million, or $1.51 a share, for its three months ended June 30, compared with a loss of $284 million, or 79 cents a share, a year earlier.
